9,937 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,937 shares of the company’s stock, valued at approximately $318,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. lifted its holdings in shares of Apellis Pharmaceuticals by 85.8% during the fourth quarter. Landscape Capital Management L.L.C. now owns 49,986 shares of the company’s stock valued at $1,595,000 after purchasing an additional 23,086 shares in the last quarter. Cinctive Capital Management LP bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at about $2,776,000. Trexquant Investment LP bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at about $6,478,000. Geode Capital Management LLC lifted its holdings in Apellis Pharmaceuticals by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock valued at $58,699,000 after acquiring an additional 28,426 shares during the period. Finally, National Bank of Canada FI lifted its holdings in Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock valued at $44,214,000 after acquiring an additional 1,385,080 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on APLS shares. Wedbush decreased their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Royal Bank of Canada decreased their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Monday, March 3rd. Scotiabank increased their target price on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. increased their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.59.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Nur Nicholson sold 2,145 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $29.96, for a total value of $64,264.20. Following the sale, the insider now directly owns 52,011 shares in the company, valued at approximately $1,558,249.56. The trade was a 3.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,238 shares of company stock valued at $1,857,510 over the last three months. 6.80% of the stock is owned by company insiders.

Apellis Pharmaceuticals Trading Up 4.9 %

Shares of APLS stock opened at $19.61 on Thursday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market capitalization of $2.46 billion, a PE ratio of -9.66 and a beta of 0.85. Apellis Pharmaceuticals, Inc. has a 1-year low of $17.72 and a 1-year high of $57.85. The business’s fifty day moving average price is $25.19 and its 200 day moving average price is $28.52.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. During the same quarter in the prior year, the firm earned ($0.73) EPS. Apellis Pharmaceuticals’s quarterly revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).